Early-Stage Biotech Gets $1.3B Boost From New Investor
Frazier Life Sciences has secured $1.3 billion for early-stage biotech investing, making it the third major firm in recent months to raise significant capital. In a market showing both resilience and selectivity, the fund highlights where opportunity and investor conviction remains strong.
German 
English